Among them, trastuzumab, the first FDA-approved HER2-targeting drug, still remains the most commonly used drug of molecular targeted therapy for HER2-positive breast cancer, improving the survival of patients with this molecular subtype (Kreutzfeldt et al., 2020; Wang et al., 2022). This evidence concerns the gene ERBB2 and breast carcinoma.